The global connected drug delivery devices market was valued at USD 361.1 million in 2018 and is anticipated to reach approximately USD 25,810.9 million by 2032, growing at a robust CAGR of 35.7% during the forecast period from 2018 to 2032. In 2018, North America led the market, accounting for a dominant share of 70.06%.

The global connected drug delivery devices market has experienced significant growth in recent years and is expected to expand rapidly over the forecast period. This growth is driven by increasing demand for smart healthcare solutions that enhance patient adherence, enable real-time monitoring, and improve treatment outcomes. The integration of digital technologies such as IoT, mobile health applications, and cloud-based platforms is transforming drug delivery practices. Regions like North America have been at the forefront of adoption due to advanced healthcare infrastructure and favorable regulatory frameworks. As awareness and access to connected therapeutics continue to rise globally, the market is poised for substantial expansion in the coming years.

Continue reading for more details:

**https://www.fortunebusinessinsights.com/industry-reports/connected-drug-delivery-devices-market-100380**

Market Segmentation

By Product Type

• Smart inhalers
• Connected insulin pens
• Wearable injectors
• Connected autoinjectors
• Infusion pumps

By Connectivity

• Bluetooth-enabled devices
• Wi-Fi-connected systems
• Cellular-connected platforms

By Therapeutic Application

• Diabetes management
• Asthma and COPD
• Oncology